Shattuck Labs, Inc.'s Chief Medical Officer, Arundathy N. Pandite, recently completed the sale of company common stock. On May 12, 2026, Ms. Pandite sold a total of 30,000 shares, amounting to $198,300. The weighted average selling price for these shares was determined to be $6.61 per share.
This insider transaction took place against the backdrop of substantial stock performance for Shattuck Labs. Over the preceding year, the company's shares recorded a 574% return, and within the last six months, those shares had achieved a 255% gain. The sale itself was structured under a Rule 10b5-1 trading plan that Ms. Pandite established on February 2, 2026.
The specific execution of these trades saw prices ranging from $6.41 to $7.03 per share, inclusive. Following the completion of this transaction, records indicate that Ms. Pandite directly holds a total of 166,219 shares of Shattuck Labs common stock.
Beyond the personal trading activity, recent corporate developments provide additional context for evaluating Shattuck Labs' prospects. Notably, TD Cowen has reiterated its Buy rating concerning the company. This positive assessment followed a detailed evaluation of SL-325, which is identified as the company’s primary drug candidate. SL-325 functions as an anti-DR3 monoclonal antibody designed with the specific goal of blocking the DR3-TL1A axis.
The technical foundation supporting TD Cowen's positive outlook involves toxicology studies conducted in non-human primates. These studies revealed a favorable safety profile for SL-325. Specifically, the data showed that complete and durable receptor occupancy could be maintained for a duration of two to four weeks. Crucially, these findings were documented at or below the no-observed-adverse-effect level of 100 mg/kg. These positive findings contribute to TD Cowen's overall favorable view regarding Shattuck Labs' potential.
In terms of valuation analysis, third-party assessment from InvestingPro suggests that the stock currently appears overvalued relative to its calculated Fair Value. Despite this valuation concern, industry analysts have maintained a range of price targets for the company, suggesting valuations between $7 and $18 per share.
The information presented highlights both significant operational progress through drug development and external analyst support, alongside recent insider selling amid strong market gains and current valuation concerns.